Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief strategy officer said. Mitsubishi Tanabe Pharma is being sold to Bain Capital for about $3.3 billion. Eisai expects a Leqembi “expansion phase” on the horizon.
read moreBristol Myers Squibb is striking out in its attempts to broaden the label of its first-in-class combo drug Opdualag. On Thursday, the company revealed that a phase 3 trial of Opdualag as an adjuvant treatment for patients with completely resected
read moreUCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its psoriatic arthritis launch. Yet, the analysis suggests UCB has work to
read moreModerna is revamping its digital team, eliminating 10% of roles under two digital departments, a person close to the matter told Fierce Pharma. More: Moderna trims digital team, lays off employees as chief information officer departs Source: fierce
read more
Significant progress for hereditary angioedema condition More: Andembry treatment approved across Europe Source: News
read more
Imaging agent to improve prostate cancer detection More: Illuccix therapy gets approval in the UK Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals